ライフサイエンスコーパス: blind end

1 ts, tortuous vessels, and blood vessels with blind ends.

2 nel Nav1.3, as well as Nav1.7 and Nav1.8, in blind-ending axons within human painful neuromas.

3 sively branched relative to controls, formed blind-ended 'bulbs' filled with mitochondria, and were s

4 Moreover, LECs in blind-ended capillaries and around valves in pre-collect

5 d primarily in the suprachoroidea, and their blind-ended capillary branches enter the choriocapillari

6 /+) retinas displayed an increased number of blind-ended capillary sprout tips (P < 0.02) and endothe

7 ar processes including neovascular tufts and blind-ended capillary sprouts.

8 ened and/or curly tail, no genital tubercle, blind-ended colons, hydronephrotic kidneys, and no bladd

9 ne with a large-diameter cell body, a large, blind-ending dendrite, and a giant ovoid, axon measuring

10 of Yap leads to hydronephrotic kidneys with blind-ending megaureters at birth.

11 unanticipated finding was the influence of a blind-end microvessel on model convergence, indicating a

12 ureters and hence absent homolateral kidney; blind ending (obstructed) ipsilateral hemivagina and ces

13 Three-dimensional analysis revealed blind-ending outpouches of ducts in murine and human pan

14 open-label, randomized, crossover study with blind end point evaluation to compare the efficacy and s

15 uster (hospital-level) randomized open-label blinded end point (PROBE) clinical trial using a multice

16 open-label, randomized-controlled trial with blinded end point adjudication in intensive care unit-le

17 randomized, single-blind, 24-week study with blinded end point assessment among anemic (average hemog

18 andomized, controlled superiority trial with blinded end point assessment.

19 , open-label, randomized clinical trial with blinded end point assessment.

20 Patients were evaluated by a blinded end point assessment.

21 PARTICIPANTS: Prospective, randomized, open-blinded end point clinical trial in 7 hospitals across A

22 gle-center prospective randomized open-label blinded end point clinical trial.

23 t, pragmatic, prospective, randomized, open, blinded end point controlled trial conducted in 12 Spani

24 enter clinical trial of parallel groups with blinded end point design conducted in 24 teaching hospit

25 p, open-label randomized clinical trial with blinded end point evaluation conducted at 19 centers in

26 al was a multicenter randomized, open-label, blinded end point evaluation that enrolled 408 patients

27 llel-group, open-label treatment trials with blinded end point evaluation that met inclusion criteria

28 SETTING, AND PARTICIPANTS: This open-label, blinded end point randomized clinical trial was conducte

29 multicenter, prospective, randomized, open, blinded end point superiority clinical trial conducted a

30 Randomized, open-label, blinded end point trial (PREPIC2) with 6-month follow-up

31 ulticentre prospective randomized open-label blinded end point trial of combination beta-adrenergic r

32 -group, prospective, randomized, open-label, blinded end point trial, consenting patients with type 2

33 In this prospective, randomized, open-label, blinded end point trial, in a single UK hospital, 220 wo

34 open-label randomized clinical trial with a blinded end point was conducted from August 10, 2019, to

35 initiated PROBE (prospective randomized open blinded end point) outcome assessment trial, randomized

36 linical trial, with open-label treatment and blinded end point, conducted from February 2, 2018, to J

37 hrough May 31, 2018, this prospective, open, blinded end point, parallel-group randomized clinical tr

38 G, AND PARTICIPANTS: Randomized, open-label, blinded end point, phase 2, futility clinical trial that

39 ternational, multicentre, prospective, open, blinded end point, randomised controlled trials of patie

40 CIPANTS: This was a multicenter, open-label, blinded end point, randomized clinical trial conducted a

41 points (PROBE [Prospective Randomized Open, Blinded End Point] design).

42 G, AND PARTICIPANTS: Randomized, open-label, blinded, end point trial set in a single hospital in the

43 SIGN, SETTING, AND PARTICIPANTS: Open-label, blinded-end point, bayesian-adaptive randomized trial wi

44 ized, open-allocation, controlled trial with blinded end-point adjudication.

45 (ASTER) study was a randomized, open-label, blinded end-point clinical trial conducted in 8 comprehe

46 G, AND PARTICIPANTS: Randomized, open-label, blinded end-point clinical trial including 160 patients

47 After 30 days, a blinded end-point committee assessed whether a combined

48 Strokes were adjudicated by a blinded end-point committee using standard clinical and

49 hase 2, prospective, randomised, open-label, blinded end-point evaluation study, adults with supraten

50 lel-group, open-label treatment trial with a blinded end-point evaluation to compare GA with CS for t

51 In an open-label, randomized trial with blinded end-point evaluation, conducted in Denmark and N

52 In a multicenter, open-label trial with blinded end-point evaluation, we randomly assigned adult

53 mined 3 months beyond catheter ablation by a blinded end-point evaluation.

54 sed, randomized, noninferiority, open-label, blinded end-point study at 34 stroke units using the Swe

55 center, prospective, randomized, open-label, blinded end-point trial, patients with breast cancer and

56 ) was an investigator-initiated, open-label, blinded end-point, randomized clinical trial with a 2 x

57 NG, AND PARTICIPANTS: Randomized, open-label blinded-end-point trial enrolling 788 patients hospitali

58 This trial was a prospective, randomized, blinded end-points study in patients >=75 years of age w

59 Prospective, open-label blinded end-points trial (A Study to Evaluate the Effect

60 Blind-ending sprouts were extremely rare.

61 epithelium mimicking geographic atrophy, the blinding end-stage condition characteristic of the dry f

62 The distal tip cell (DTC) caps a blind-ended tube; only the distal germ cells maintain pr

63 The lymphatic system comprises blind-ended tubes that collect interstitial fluid and re

64 surface by a radial channel which becomes a blind-ended tunnel in the tetramer, and probably acts as

65 (pre-existing vessels, angiogenic plexus and blind-ended vessels (BEVs)) was quantified using in vivo

66 Blood enters these blind-ending vessels from the ventral aorta, distending